Grace Therapeutics Inc. (GRCE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Grace Therapeutics Inc.

    NASDAQ: GRCE · Real-Time Price · USD
    3.20
    0.14 (4.58%)
    At close: Sep 05, 2025, 3:59 PM
    3.20
    0.06%
    Pre-market: Sep 08, 2025, 08:02 AM EDT

    Grace Therapeutics Income Statement

    Financials in USD. Fiscal year is April - March.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 7K 11K 124K n/a
    Gross Profit
    		 -7K -11K -124K n/a
    Operating Income
    		 -16.68M -12.85M -52.16M -15.59M
    Interest Income
    		 711K 911K 246K 77K
    Pretax Income
    		 -12.77M -14.69M -51.97M -10.47M
    Net Income
    		 -12.77M -12.85M -42.43M -9.82M
    Selling & General & Admin
    		 7.17M 6.64M 8.21M 9.78M
    Research & Development
    		 9.51M 4.68M 9.97M 5.56M
    Other Expenses
    		 n/a 1.52M 33.97M 249K
    Operating Expenses
    		 16.68M 12.85M 52.16M 15.59M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a 194K 136K 116K
    Cost & Expenses
    		 16.68M 12.85M 52.16M 15.59M
    Income Tax Expense
    		 -3.2M -1.83M -9.54M -648K
    Shares Outstanding (Basic)
    		 12.09M 7.44M 7.43M 6.14M
    Shares Outstanding (Diluted)
    		 12.09M 7.44M 7.43M 6.14M
    EPS (Basic)
    		 -0.79 -1.73 -5.71 -1.6
    EPS (Diluted)
    		 -0.79 -1.73 -5.71 -1.6
    EBITDA
    		 -12.76M -11.33M -18.12M -15.34M
    EBIT
    		 -12.77M -11.37M -18.25M -15.34M
    Depreciation & Amortization
    		 7K 11K 124K n/a

    Add to Watchlist